SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it has launched BRCATrueTM, a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.
Help employers find you! Check out all the jobs and post your resume.
